Molecular Oncology
@moloncology.bsky.social
Open access journal highlighting new discoveries, technical developments and policies in basic, translational, and clinical cancer research. Part of FEBS Press.
moloncol.org
moloncol.org
📑 New Review for your reading list
Cis-regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation
🔓 buff.ly/g5WeXxC
@Dr_Alex_Eustace #ncRNA #BCSM #Biomarkers
Cis-regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation
🔓 buff.ly/g5WeXxC
@Dr_Alex_Eustace #ncRNA #BCSM #Biomarkers
November 24, 2025 at 9:01 AM
📑 New Review for your reading list
Cis-regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation
🔓 buff.ly/g5WeXxC
@Dr_Alex_Eustace #ncRNA #BCSM #Biomarkers
Cis-regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation
🔓 buff.ly/g5WeXxC
@Dr_Alex_Eustace #ncRNA #BCSM #Biomarkers
Detection of circulating tumor DNA in colorectal cancer patients using a methylation-specific droplet digital PCR multiplex
🔓 buff.ly/CG0J1Ck
#ctDNA #ddPCR #CRC #Epigenetics #CancerDiagnostics #Biomarkers
🔓 buff.ly/CG0J1Ck
#ctDNA #ddPCR #CRC #Epigenetics #CancerDiagnostics #Biomarkers
November 21, 2025 at 9:00 AM
Detection of circulating tumor DNA in colorectal cancer patients using a methylation-specific droplet digital PCR multiplex
🔓 buff.ly/CG0J1Ck
#ctDNA #ddPCR #CRC #Epigenetics #CancerDiagnostics #Biomarkers
🔓 buff.ly/CG0J1Ck
#ctDNA #ddPCR #CRC #Epigenetics #CancerDiagnostics #Biomarkers
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
🔦 buff.ly/hlA2obL
#PARPi #BladderCancer #BRCA #
🔦 buff.ly/hlA2obL
#PARPi #BladderCancer #BRCA #
November 20, 2025 at 9:30 AM
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
🔦 buff.ly/hlA2obL
#PARPi #BladderCancer #BRCA #
🔦 buff.ly/hlA2obL
#PARPi #BladderCancer #BRCA #
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
👉 buff.ly/WGihs9T
#Chemotherapy #Metastasis #CRCSM
👉 buff.ly/WGihs9T
#Chemotherapy #Metastasis #CRCSM
November 19, 2025 at 9:45 AM
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
👉 buff.ly/WGihs9T
#Chemotherapy #Metastasis #CRCSM
👉 buff.ly/WGihs9T
#Chemotherapy #Metastasis #CRCSM
🚨 New Review alert - don't miss this
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
November 18, 2025 at 10:00 AM
🚨 New Review alert - don't miss this
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
🚨 New Review alert - don't miss this
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
November 18, 2025 at 9:30 AM
🚨 New Review alert - don't miss this
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
Strength through diversity: how cancers thrive when clones cooperate
🔓 buff.ly/kQAi97p
#TumourHeterogeneity #TherapyResistance #CancerResistance
❄️ Don't miss our November Issue🌨️
📗 Cytomegalovirus (pp71-green) in primary prostate cancer (pan-keratin red)
📑 EACR Viewpoint on clinical KRAS/RAS inhibitors & novel strategies for RAS-mutant cancers @ciccancer.bsky.social
🔓 buff.ly/NpZSen9
#NSCLC #LUAD #Hypoxia #LungCancer
📗 Cytomegalovirus (pp71-green) in primary prostate cancer (pan-keratin red)
📑 EACR Viewpoint on clinical KRAS/RAS inhibitors & novel strategies for RAS-mutant cancers @ciccancer.bsky.social
🔓 buff.ly/NpZSen9
#NSCLC #LUAD #Hypoxia #LungCancer
November 12, 2025 at 9:15 AM
❄️ Don't miss our November Issue🌨️
📗 Cytomegalovirus (pp71-green) in primary prostate cancer (pan-keratin red)
📑 EACR Viewpoint on clinical KRAS/RAS inhibitors & novel strategies for RAS-mutant cancers @ciccancer.bsky.social
🔓 buff.ly/NpZSen9
#NSCLC #LUAD #Hypoxia #LungCancer
📗 Cytomegalovirus (pp71-green) in primary prostate cancer (pan-keratin red)
📑 EACR Viewpoint on clinical KRAS/RAS inhibitors & novel strategies for RAS-mutant cancers @ciccancer.bsky.social
🔓 buff.ly/NpZSen9
#NSCLC #LUAD #Hypoxia #LungCancer
📑 If you are working on the interface of hypoxia and cancer research, this may be your cup of tea!
🦮 A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications
🔓 buff.ly/wrD6w1r
#ROS #Hypoxia #TumourMicroenvironment
🦮 A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications
🔓 buff.ly/wrD6w1r
#ROS #Hypoxia #TumourMicroenvironment
November 10, 2025 at 9:01 AM
📑 If you are working on the interface of hypoxia and cancer research, this may be your cup of tea!
🦮 A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications
🔓 buff.ly/wrD6w1r
#ROS #Hypoxia #TumourMicroenvironment
🦮 A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications
🔓 buff.ly/wrD6w1r
#ROS #Hypoxia #TumourMicroenvironment
Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer
➡️ buff.ly/SZQZJaL
#HDAC #Oxaliplatin #CRCSM
➡️ buff.ly/SZQZJaL
#HDAC #Oxaliplatin #CRCSM
November 7, 2025 at 8:30 AM
Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer
➡️ buff.ly/SZQZJaL
#HDAC #Oxaliplatin #CRCSM
➡️ buff.ly/SZQZJaL
#HDAC #Oxaliplatin #CRCSM
The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity
👉 buff.ly/tJzVEhb
#Melanoma #MELCSM #ImmunoOnc
👉 buff.ly/tJzVEhb
#Melanoma #MELCSM #ImmunoOnc
November 6, 2025 at 9:30 AM
The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity
👉 buff.ly/tJzVEhb
#Melanoma #MELCSM #ImmunoOnc
👉 buff.ly/tJzVEhb
#Melanoma #MELCSM #ImmunoOnc
🚨 New EACR Viewpoint alert
The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies
🔓 buff.ly/05MSKU1
#RASinhibitors #TherapyResistance #CancerResearch @helloeacr.bsky.social
The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies
🔓 buff.ly/05MSKU1
#RASinhibitors #TherapyResistance #CancerResearch @helloeacr.bsky.social
November 5, 2025 at 8:45 AM
🚨 New EACR Viewpoint alert
The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies
🔓 buff.ly/05MSKU1
#RASinhibitors #TherapyResistance #CancerResearch @helloeacr.bsky.social
The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies
🔓 buff.ly/05MSKU1
#RASinhibitors #TherapyResistance #CancerResearch @helloeacr.bsky.social
🗣️New meeting announced
🟨 "Cancer Metabolism"🟨
📅 It's not too late to plan ahead
Submit abstracts by Jun 29 2026
⌛️Register by Sept 7 2026
🗓️Oct 6-8 2026
🖱️https://buff.ly/s88vxNH
#CancerMetabolism #Metabolism
#MetabolicReprogramming #CancerResearch
🟨 "Cancer Metabolism"🟨
📅 It's not too late to plan ahead
Submit abstracts by Jun 29 2026
⌛️Register by Sept 7 2026
🗓️Oct 6-8 2026
🖱️https://buff.ly/s88vxNH
#CancerMetabolism #Metabolism
#MetabolicReprogramming #CancerResearch
November 4, 2025 at 9:00 AM
🗣️New meeting announced
🟨 "Cancer Metabolism"🟨
📅 It's not too late to plan ahead
Submit abstracts by Jun 29 2026
⌛️Register by Sept 7 2026
🗓️Oct 6-8 2026
🖱️https://buff.ly/s88vxNH
#CancerMetabolism #Metabolism
#MetabolicReprogramming #CancerResearch
🟨 "Cancer Metabolism"🟨
📅 It's not too late to plan ahead
Submit abstracts by Jun 29 2026
⌛️Register by Sept 7 2026
🗓️Oct 6-8 2026
🖱️https://buff.ly/s88vxNH
#CancerMetabolism #Metabolism
#MetabolicReprogramming #CancerResearch
Survivin and Aurora Kinase A control cell fate decisions during mitosis
👉 buff.ly/PLDmH38
#AURKA #Mitosis #CellFate
👉 buff.ly/PLDmH38
#AURKA #Mitosis #CellFate
November 3, 2025 at 10:01 AM
Survivin and Aurora Kinase A control cell fate decisions during mitosis
👉 buff.ly/PLDmH38
#AURKA #Mitosis #CellFate
👉 buff.ly/PLDmH38
#AURKA #Mitosis #CellFate
A synthetic benzoxazine dimer derivative targets c-Myc to inhibit colorectal cancer progression
➡️ buff.ly/czDTEB0
#CRCSM #CancerResearch
➡️ buff.ly/czDTEB0
#CRCSM #CancerResearch
October 31, 2025 at 10:01 AM
A synthetic benzoxazine dimer derivative targets c-Myc to inhibit colorectal cancer progression
➡️ buff.ly/czDTEB0
#CRCSM #CancerResearch
➡️ buff.ly/czDTEB0
#CRCSM #CancerResearch
Aggressive prostate cancer is associated with pericyte dysfunction
👉 buff.ly/hbBYh67
🖊️ @idibell_cat @ArkaitzLab
#ProstateCancer #PCSM #Pericyte
👉 buff.ly/hbBYh67
🖊️ @idibell_cat @ArkaitzLab
#ProstateCancer #PCSM #Pericyte
October 30, 2025 at 9:48 AM
Aggressive prostate cancer is associated with pericyte dysfunction
👉 buff.ly/hbBYh67
🖊️ @idibell_cat @ArkaitzLab
#ProstateCancer #PCSM #Pericyte
👉 buff.ly/hbBYh67
🖊️ @idibell_cat @ArkaitzLab
#ProstateCancer #PCSM #Pericyte
📣The joint publishing fellowship with the @EACRnews offers a remote placement at
@MolOncology
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
@MolOncology
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
October 28, 2025 at 5:11 PM
📣The joint publishing fellowship with the @EACRnews offers a remote placement at
@MolOncology
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
@MolOncology
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
🎃 Our October issue is online👻
❗ Read the EACR Viewpoint article by Gerlanda Vella and Maria Rescigno on the role of tumour-associated bacteria and their interplay with the tumour microenvironment in modulating cancer progression
🔓 buff.ly/xsyuvqP
#Neuroendocrine #Histopathology #CancerResearch
❗ Read the EACR Viewpoint article by Gerlanda Vella and Maria Rescigno on the role of tumour-associated bacteria and their interplay with the tumour microenvironment in modulating cancer progression
🔓 buff.ly/xsyuvqP
#Neuroendocrine #Histopathology #CancerResearch
October 20, 2025 at 11:30 AM
🎃 Our October issue is online👻
❗ Read the EACR Viewpoint article by Gerlanda Vella and Maria Rescigno on the role of tumour-associated bacteria and their interplay with the tumour microenvironment in modulating cancer progression
🔓 buff.ly/xsyuvqP
#Neuroendocrine #Histopathology #CancerResearch
❗ Read the EACR Viewpoint article by Gerlanda Vella and Maria Rescigno on the role of tumour-associated bacteria and their interplay with the tumour microenvironment in modulating cancer progression
🔓 buff.ly/xsyuvqP
#Neuroendocrine #Histopathology #CancerResearch
Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
➡️ buff.ly/OpVpLqS
#Pharmacogenomics
➡️ buff.ly/OpVpLqS
#Pharmacogenomics
October 6, 2025 at 9:15 AM
Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
➡️ buff.ly/OpVpLqS
#Pharmacogenomics
➡️ buff.ly/OpVpLqS
#Pharmacogenomics
📄 Did you know we publish EACR Viewpoints?
📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the
EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch.
🔓 You may access them here
➡️ bit.ly/4cIqPCh
@FEBSnews #CancerBiology
📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the
EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch.
🔓 You may access them here
➡️ bit.ly/4cIqPCh
@FEBSnews #CancerBiology
October 3, 2025 at 9:01 AM
📄 Did you know we publish EACR Viewpoints?
📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the
EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch.
🔓 You may access them here
➡️ bit.ly/4cIqPCh
@FEBSnews #CancerBiology
📣 Introduced in 2023 when Molecular Oncology became the affiliate journal of the
EACR, EACR Viewpoints showcase authoritative opinions on cutting-edge topics in #CancerResearch.
🔓 You may access them here
➡️ bit.ly/4cIqPCh
@FEBSnews #CancerBiology
📣 New month, new Commentary
Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia
🔓 buff.ly/hO4fJ9g
🖊️ @andreaventura.bsky.social
#eccDNA #ecDNA
Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia
🔓 buff.ly/hO4fJ9g
🖊️ @andreaventura.bsky.social
#eccDNA #ecDNA
October 2, 2025 at 8:48 AM
📣 New month, new Commentary
Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia
🔓 buff.ly/hO4fJ9g
🖊️ @andreaventura.bsky.social
#eccDNA #ecDNA
Not just a by-product: circular DNA molecules derived from V(D)J recombination are linked to worse prognosis in B-cell leukemia
🔓 buff.ly/hO4fJ9g
🖊️ @andreaventura.bsky.social
#eccDNA #ecDNA
The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis
➡️ buff.ly/XfueJAy
#CTCs #mCRC #Prognosis #Oncology #CRCSM
➡️ buff.ly/XfueJAy
#CTCs #mCRC #Prognosis #Oncology #CRCSM
October 1, 2025 at 9:02 AM
The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis
➡️ buff.ly/XfueJAy
#CTCs #mCRC #Prognosis #Oncology #CRCSM
➡️ buff.ly/XfueJAy
#CTCs #mCRC #Prognosis #Oncology #CRCSM
📖 Have you leafed through our September Issue?
This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TME’s dynamic landscape
🔓 buff.ly/jYUuWIM
#TumourMicroenvironment
This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TME’s dynamic landscape
🔓 buff.ly/jYUuWIM
#TumourMicroenvironment
September 30, 2025 at 8:58 AM
📖 Have you leafed through our September Issue?
This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TME’s dynamic landscape
🔓 buff.ly/jYUuWIM
#TumourMicroenvironment
This Issue contains recent findings on how TME changes can alter cell function and treatment outcomes. It also highlights new therapeutic opportunities based on the TME’s dynamic landscape
🔓 buff.ly/jYUuWIM
#TumourMicroenvironment
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia
➡️ buff.ly/yxF616I
🖊️ @HeckmanLab
#AML #MCL1 #HemOnc
➡️ buff.ly/yxF616I
🖊️ @HeckmanLab
#AML #MCL1 #HemOnc
September 29, 2025 at 9:01 AM
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia
➡️ buff.ly/yxF616I
🖊️ @HeckmanLab
#AML #MCL1 #HemOnc
➡️ buff.ly/yxF616I
🖊️ @HeckmanLab
#AML #MCL1 #HemOnc
🤩 We are excited to be attending 🧠EACR Cancer Neuroscience🧠 next month
👥 Are you going?
👉 buff.ly/lTaWPhW
#CancerResearch #BrainTumours
#CNScancer #NeuroOncology
👥 Are you going?
👉 buff.ly/lTaWPhW
#CancerResearch #BrainTumours
#CNScancer #NeuroOncology
September 26, 2025 at 9:01 AM
🤩 We are excited to be attending 🧠EACR Cancer Neuroscience🧠 next month
👥 Are you going?
👉 buff.ly/lTaWPhW
#CancerResearch #BrainTumours
#CNScancer #NeuroOncology
👥 Are you going?
👉 buff.ly/lTaWPhW
#CancerResearch #BrainTumours
#CNScancer #NeuroOncology
📣The joint publishing fellowship with the EACR @helloeacr offers a remote placement at the journal
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
September 25, 2025 at 9:01 AM
📣The joint publishing fellowship with the EACR @helloeacr offers a remote placement at the journal
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology
Get hands-on experience in scientific editing and visit the Heidelberg office
⏰Deadline Nov 7
➡️https://buff.ly/3ZtvMe3
#PhDchat #PostDocChat #ECRchat
#CancerResearch #CancerBiology